The worldwide pharmaceutical industry is faced with a flourishing counterfeit drugs marketplace, a supply of unfair competition that harms advanced and generic businesses, and moreover, places countless lives at risk. Despite rigorous enforcement efforts and policies, the issue of counterfeit drugs carries on to exist and grow by dangerous percentages. Counterfeit medicine is fake medicine. It might be infected or include the wrong or no active component. They might have the right active ingredient, but at the wrong dose.

The problem of counterfeit drugs inside the global pharmaceutical industry is compounded by its complicated and opaque supply chain. Such illegal operations have led to more than 100, 000 deaths all around the world. During its 2016 Operation Pangea, a combined team from 103 nations seized greater than $53 million worth of possibly dangerous medications and suspended 4, 932 web sites selling illicit pharmaceuticals. While this emphasizes success for regulators, it always displays that expansion in the size of the pharmaceutical counterfeit marketplace over these years. The business continues to be under extraordinary pressure to put mechanisms to check the misuse of its supply chain and ensure credibility of products by stopping up the entry of fake drugs to the supply chain particularly the part – between the producer and consumer.



複雑で不透明なサプライチェーンによって、世界の製薬業界の偽造品の問題は複雑化しています。このような違法行為は世界中で100,000人以上の死者を出しました。 2016年のパンゲア・オペレーションでは、103カ国からなる合同チームが、危険な医薬品を5300万ドル以上摘発し、不正な医薬品を販売する4,932のウェブサイトを中断させました。これは規制当局の成功を示す一方で、医薬品偽造市場規模が拡大していることを示しています。このビジネスは、サプライチェーンの悪用をチェックし、サプライチェーン、特にプロデューサーと消費者との間の部分への偽の薬物の侵入を止めることによって、製品の信頼性を確保する仕組みを置くという強い圧力を受け続けています。